Zipfel P - Search Results

1

Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

McMahon N, Cheng TY, Beasley GM, Spasojevic I, Petros W, Augustine CK, Zipfel P, Padussis JC, Sanders G, Tyler DS. McMahon N, et al. Among authors: zipfel p. Ann Surg Oncol. 2009 Apr;16(4):953-61. doi: 10.1245/s10434-008-0288-1. Epub 2009 Jan 30. Ann Surg Oncol. 2009. PMID: 19184236 Free PMC article.

2

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.

Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y, Selim MA, Burchette J, Beasley GM, McMahon N, Padussis J, Pruitt SK, Ali-Osman F, Tyler DS. Augustine CK, et al. Mol Cancer Ther. 2010 Jul;9(7):2090-101. doi: 10.1158/1535-7163.MCT-10-0073. Epub 2010 Jun 22. Mol Cancer Ther. 2010. PMID: 20571072

3

Enhancing melanoma treatment with resveratrol.

Osmond GW, Augustine CK, Zipfel PA, Padussis J, Tyler DS. Osmond GW, et al. J Surg Res. 2012 Jan;172(1):109-15. doi: 10.1016/j.jss.2010.07.033. Epub 2010 Aug 6. J Surg Res. 2012. PMID: 20855085

4

Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.

Yoshimoto Y, Augustine CK, Yoo JS, Zipfel PA, Selim MA, Pruitt SK, Friedman HS, Ali-Osman F, Tyler DS. Yoshimoto Y, et al. Mol Cancer Ther. 2007 May;6(5):1492-500. doi: 10.1158/1535-7163.MCT-06-0718. Epub 2007 May 4. Mol Cancer Ther. 2007. PMID: 17483437

5

Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.

Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA, Febbo P, Pendergast AM, Peters WP, Tyler DS. Augustine CK, et al. Among authors: zipfel pa. Cancer Res. 2008 May 15;68(10):3777-84. doi: 10.1158/0008-5472.CAN-07-5949. Cancer Res. 2008. PMID: 18483261

6

Genomic and molecular profiling predicts response to temozolomide in melanoma.

Augustine CK, Yoo JS, Potti A, Yoshimoto Y, Zipfel PA, Friedman HS, Nevins JR, Ali-Osman F, Tyler DS. Augustine CK, et al. Clin Cancer Res. 2009 Jan 15;15(2):502-10. doi: 10.1158/1078-0432.CCR-08-1916. Clin Cancer Res. 2009. PMID: 19147755

7

Ral activation promotes melanomagenesis.

Zipfel PA, Brady DC, Kashatus DF, Ancrile BD, Tyler DS, Counter CM. Zipfel PA, et al. Oncogene. 2010 Aug 26;29(34):4859-64. doi: 10.1038/onc.2010.224. Epub 2010 Jun 21. Oncogene. 2010. PMID: 20562921 Free PMC article.

8

Novel anticancer compounds induce apoptosis in melanoma cells.

Bhat UG, Zipfel PA, Tyler DS, Gartel AL. Bhat UG, et al. Cell Cycle. 2008 Jun 15;7(12):1851-5. doi: 10.4161/cc.7.12.6032. Epub 2008 Jun 30. Cell Cycle. 2008. PMID: 18583930

9

Requirement for Abl kinases in T cell receptor signaling.

Zipfel PA, Zhang W, Quiroz M, Pendergast AM. Zipfel PA, et al. Curr Biol. 2004 Jul 27;14(14):1222-31. doi: 10.1016/j.cub.2004.07.021. Curr Biol. 2004. PMID: 15268851 Free article.

10

Role for the Abi/wave protein complex in T cell receptor-mediated proliferation and cytoskeletal remodeling.

Zipfel PA, Bunnell SC, Witherow DS, Gu JJ, Chislock EM, Ring C, Pendergast AM. Zipfel PA, et al. Curr Biol. 2006 Jan 10;16(1):35-46. doi: 10.1016/j.cub.2005.12.024. Curr Biol. 2006. PMID: 16401422 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

387 results

Search Page

Filters